![]() |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vol. 305, Issue 2, 786-795, May 2003
Department of Neurosciences, University of Pisa, Pisa, Italy
The muscarinic M2 receptor was split at the third
cytoplasmic loop into two fragments: the one containing the first five
transmembrane regions and the N-terminal part of the third cytoplasmic
loop was named M2trunk, while the other, which contained
the last two transmembrane regions and the C-terminal part of the third
cytoplasmic loop, was named M2tail. As seen in many other G
protein-coupled receptors, when these two fragments were transfected
together in COS-7 cells they rescued the pharmacological profile and
the functional activity of the wild-type M2 receptor.
Conversely, N-[3H]methylscopolamine
([3H]NMS) association binding experiments showed a
substantial difference between the wild-type M2 and the
split M2trunk/M2tail receptors. The progression
of the association binding kinetic of the
M2trunk/M2tail receptor was strictly dependent
upon the amount of the fragment DNA transfected. When the amount of
transfected DNA was 4 µg/plate and the
Bmax of [3H]NMS at equilibrium
was around 200 fmol/mg protein the form of the association was that of
classical saturation, but when the amount of transfected DNA was lower
the [3H]NMS association reached a maximum binding point
and then declined to a lower equilibrium binding level. The form of the
association was temperature-dependent: as the temperature was lowered,
the maximum binding point tended to be higher. We suggest that this peculiar form of the [3H]NMS association binding to the
muscarinic M2trunk/M2tail receptor is
attributable to a less stable interaction between the trunk and the
tail fragments of the split receptor.
This article has been cited by other articles:
![]() |
J. Jakubik, A. Krejci, and V. Dolezal Asparagine, Valine, and Threonine in the Third Extracellular Loop of Muscarinic Receptor Have Essential Roles in the Positive Cooperativity of Strychnine-Like Allosteric Modulators J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 688 - 696. [Abstract] [Full Text] [PDF] |
||||